The €500 million contract, according to MSD, follows the company's announcement last year of a €1 billion investment across its locations in Carlow and Dunboyne, Co Meath.

According to MSD Ireland, it plans to add over 1,000 jobs over the next few years at its eight locations in the counties of Carlow, Cork, Dublin, Louth, Meath, and Tipperary, including this acquisition.

Over 3,000 Irish workers are employed by the corporation at its many locations.

The formal handover procedure between WuXi and MSD will now commence, with the goal of finishing it by the first part of the year.

The Dundalk site is a three-story, 15,520-square-meter vaccine manufacturing complex with quality control labs, drug substance manufacturing, and drug product manufacturing facilities to offer vaccine goods for the worldwide market.

There are currently 200 or so employees working there.

Today's agreement, according to MSD, is evidence of the two businesses' effective cooperation and long-standing alliance, which dates back to 2019.

Since 2019, MSD and WuXi have been working together on the Dundalk site. The Dundalk location will join MSD's current nationwide network of five sizable pharmaceutical manufacturing, research, and development facilities (MSD Ballydine, MSD Brinny, MSD Carlow, MSD Dunboyne, and MSD Biotech, Dublin), as well as two locations in Dublin dedicated to animal and human health operations.